Treatment with capecitabine after surgery for biliary tract cancer improves overall survival (OS) by 15 months compared with observation after surgery, according to the BILCAP* study presented at the ASCO 2017 Annual Meeting in Chicago, Illinois, US.
The addition of pertuzumab to standard-of-care therapy may convey a positive, albeit modest, effect for women with HER2-positive breast cancer, according to findings from the APHINITY* trial presented at the annual meeting of the American Society of Clinical Oncology (ASCO 2017) held in Chicago, Illinois, US.
A single dose of radiation therapy (RT) may be enough to preserve the ability to walk in cancer patients with spinal cord compression due to metastases, according to the SCORAD III* study presented at the ASCO 2017 meeting.
Women with a history of estrogen receptor (ER)-positive breast cancer (BC) who subsequently got pregnant appears to have similar disease-free survival (DFS) as those who did not get pregnant,according to a study presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO 2017) held in Chicago, Illinois, US.
The addition of cediranib to platinum-based chemotherapy may improve overall survival (OS) in women with ovarian cancer compared with chemotherapy alone, according to the updated results of the ICON* 6 trial presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 held in Chicago, Illinois, US.
Eating tree nuts may cut the risk of cancer recurrence and death by as much as half in patients with stage III colon cancer, according to a study presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Recurrence prevention after lung cancer surgery appears to be more successful with the targeted therapy gefitinib than the standard of care, vinorelbine plus cisplatin (VP) chemotherapy, according to a study presented at the 2017 ASCO Annual Meeting in Chicago.
The second-generation ALK inhibitor alectinib significantly improves progression-free survival (PFS) with fewer adverse events (AEs) in Japanese patients with ALK-positive non-small cell lung cancer (NSCLC) compared with the current first-line therapy crizotinib, reveals an interim analysis of the J-ALEX* study. Follow-up of an additional 10 months showed similar results, as presented in the ASCO 2017 Annual Meeting.
The investigational drug aldoxorubicin failed to improve progression-free survival (PFS) in patients with soft tissue sarcoma (STS) in a new study, but investigators touted it as a potential “new generation anthracycline” that is less toxic than standard treatment.
The addition of abiraterone acetate to first-line androgen deprivation therapy (ADT) resulted in a significant improvement in overall survival (OS) in men with prostate cancer, according to the findings of the LATITUDE* and STAMPEDE** trials presented at the annual meeting of the American Society of Clinical Oncology (ASCO 2017) held in Chicago, Illinois, US.
Treatment with fludarabine, cytarabine and G-CSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (Ida) is associated with high remission rates among patients with newly diagnosed core binding factor acute myelogenous leukaemia (CBF-AML) with low induction mortalities, reports a study.
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) significantly improves response rates and depth of response in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT), according to updated results of the phase II GRIFFIN* study presented at ASH 2019.
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.